We make investments that
help fuel technologies of the future
Lam Capital invests in innovative companies that are addressing some of today’s most challenging, high-impact problems. From the industrialization of life sciences to the advancement of industrial automation, we support important technologies that are disrupting their respective industries. Our expertise in advanced nanoscale systems engineering and technology innovation guide our portfolio companies to create new realities for an ever-changing world.
We invest in companies that extend our core technologies into new markets and in synergistic technologies that help solve some of the hardest challenges across multiple disciplines. We partner with and invest in disruptive companies that are making a big impact in the following areas:
Enhance molecular profiling technologies that operate across the genomic, proteomic, or metabolic workflow, creating new insights into the inner workings of biological entities
Advance systems engineering innovation to address next-generation industrial automation
Develop innovations that advance the semiconductor ecosystem to enable the continuation of Moore's Law
Leverage our core skills and technology to create innovative products and new market opportunities
We look for companies that have the potential to transform their respective industries. Here are some of the companies in which we've invested:
The mission of startup Antheia, Inc., is to make and fairly provide medicines to all who need them. The company combines founding intellectual property with world-leading expertise in synthetic biology, informatics, and fermentation technology to provide a stable and cost-competitive supply of plant-based medicines and to transform the discovery, manufacture, and distribution of medicines.
Echopixel is building a new world of patient care with its interactive, 3D medical visualization software. The True 3D system allows medical professionals to interact with patient-specific organs and tissue in an open 3D space emanating from a display, enabling doctors to immediately identify, evaluate, and dissect clinically significant structures.
kaiaTech is dedicated to the success of its customers by being the world-class leader in providing innovative, sustainable, and cost-effective “nano-glass” barrier and coating solutions to the packaging industry. It uses semiconductor technology and applies it to food and beverage packaging to increase product shelf life. The packaging is 100% sustainable and uses a low-cost BPA-free process.
Mission Bio delivers targeted single-cell genomics solutions for high-impact applications with Tapestri, the Precision Genomics Platform. Tapestri is the industry’s first targeted single-cell DNA sequencing platform, enabling precise detection of heterogeneity in disease progression and treatment response. Application areas include blood cancers, solid tumors, and genome editing validation. The platform includes an instrument, consumables, and analysis software, which integrate seamlessly with existing NGS workflows. With Tapestri, researchers have a highly sensitive, targeted, and customizable solution to move precision medicine forward.
Spun out of research at the University of California, San Francisco, Mission Bio is headquartered in South San Francisco, California.
Omniome is developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy. Backed by leading life sciences venture investors and a proven management team, Omniome’s vision is to be the most trusted DNA sequencing platform and leader in clinical sequencing.
Reno Subsystems’ mission is to lead the semiconductor industry in developing radio frequency (RF) matching system/power generator and flow subsystem technologies to optimize process control for volume production. For 10 nm technology nodes and below, these products provide original equipment manufacturers (OEMs) differentiating performance on deposition and etch tools without requiring tool redesign. For device manufacturers, they provide an order-of-magnitude improvement in process control to enable manufacturing of leading-edge devices. Reno’s patented technologies enable the short process times necessary in plasma processes for both planar and 3D device architectures and facilitate “always on” plasma management, improving particle control, film properties, and cost efficiency.
TetraVue is the leading innovator of 4D LIDAR vision systems that empower machines to perceive the richness of our fast-paced 3D world in high definition. TetraVue’s groundbreaking 4D LIDAR combines the resolution of high definition video with the range of LIDAR to accurately capture motion and depth for large fields-of-view and distances. Its innovative 4D camera technology captures real-time images with depth perception down to each pixel, allowing it to transform markets including autonomous vehicles, machine vision and factory automation. The company is headquartered in Vista, California.
Meet Our Team
Our strategic team of top technologists and business leaders have a range of backgrounds spanning multiple disciplines. Leveraging their collective expertise, they work together to identify companies with innovative technologies that address important business needs.
Jeff has spent the past three decades in the semiconductor industry, focusing on advanced process equipment development and business growth. He joined Lam Research in 1999 and is currently the corporate vice president responsible for emerging businesses and Lam’s venture investment activity. Before that, he was chief technology officer of the Global Products Group. Jeff also managed Lam’s spin, linear, and bevel clean products and the dielectric etch business during his first 12 years at the company. He holds numerous patents and has authored several technical publications in the areas of semiconductor processing and thin-film applications. He earned his Ph.D. in chemistry from Stanford University and his B.S. degree in chemistry from the University of California, San Diego.
Faran is a founding member and Managing Director of Lam Capital. She joined Lam Research after two decades in the Semiconductor industry, which included multiple startups. Faran has developed several commercially successful products and has a track record of developing business opportunities at both startups and large companies. Faran has been an invited speaker and panelist and has served on several technical committees. She has authored more than 60 peer reviewed papers and has been granted 26 patents. Faran earned a B.S. and M.S. in Electrical Engineering from University of Colorado in Boulder and M.S. in Management from Graduate School of Business at Stanford.
Murali oversees investments in the genomics life sciences space. Prior to joining Lam Capital, Murali built and managed teams across advanced research, technology development, product development, and operations at Illumina, and was a key contributor towards enabling the $1000 genome and beyond. In addition to driving strategic initiatives and partnerships across the healthcare and semiconductor industries, he has a strong track record of developing commercially successful products in the healthcare tools space, including Illumina’s sequencing instruments, that have cumulatively generated over $1B in revenue. Murali is an author on more than 20 patents and patent applications and has authored written more than 15 peer-reviewed publications. He earned a Ph.D. in electrical and computer engineering from the University of Illinois at Urbana-Champaign and B.Sc. and B.E. degrees in pure mathematics, computer science, and electrical engineering from the University of Western Australia.
Hash develops and executes strategies for entering new business areas that leverage Lam’s core capabilities and technology. He also identifies target companies and businesses in these market areas for investments and partnerships. Prior to joining Lam Research, he was president and CEO of SBA Materials. He has also held numerous executive-level positions at technology startups and multi-nationals, including managing MEMS Microphones P&L at Knowles Electronics/Dover Corporation and serving as vice president of business development at Cambrios Technologies. Hash is an author on more than 20 patents and patent applications and has written more than 40 peer-reviewed publications. He earned his Ph.D. and B.S. degrees in physics from the University of California, Santa Barbara.
Vikram leads Lam Capital’s life sciences investments, focusing on technologies that leverage Lam’s expertise. Prior to joining Lam Research, he led McKinsey and Company’s Life Sciences Tools practice and was a technical contributor to the Personalized Medicine practice, where he worked with pharmaceutical, medical device, and biotechnology companies on a range of operational and business development strategies. He also led product development for genomics and proteomics platforms and business development for high-potency pharmaceuticals. He has been an invited speaker and reviewer and has authored 24 peer-reviewed publications. He earned his Ph.D., M.S., and B.S. degrees in electrical engineering and biological systems instrumentation from the University of Illinois-Urbana Champaign.
Yuan-Ping leads investments in the proteomic profiling technologies space. Prior to joining Lam Capital, he was an associate at McKinsey & Company, where he advised global pharmaceutical clients on R&D and operations including technology assessment, product evaluation, sourcing decisions, and cost optimization. Specifically, Yuan-Ping developed in-depth company and market analysis which informed product expansion strategies targeting multibillion dollar sales opportunities. His earlier experience includes project management and research for medical and life sciences companies. He is a contributing author for several papers on neural development and cancer in peer-reviewed journals. Yuan-Ping earned a Ph.D. in biomedical sciences from Columbia University as well as an M.S. degree in molecular medicine and a B.S. degree in zoology from National Taiwan University.
What we do
We focus on young companies involved in life sciences, industrial automation and manufacturing, the extension of semiconductor technologies into new markets, and our core ecosystem. Funding ranges from $1-3 million per round for Series A and B investments. We also co-invest with other venture capital firms and corporate investors who share our interests.
In addition to investing financially, we create value by offering operational expertise and access to our diverse pool of technology experts and our supply chain. Our goal is to partner with our portfolio companies and help them grow and scale by leveraging our global infrastructure.